Home
 /
Papers
 /
Cancer Biology
 /
Single recipient cell tracking of tellurium-labeled extracellular vesicle proteomes (TeLEV) identifies EV-driven immunomodulation
Preprint
Open access
V1
Top 1% · Validated by QED

Single recipient cell tracking of tellurium-labeled extracellular vesicle proteomes (TeLEV) identifies EV-driven…

Daniel Bachurski, Rahil Gholamipoorfard, Yong-Jia Bu +40 more
January 2026
 ·
bioRxiv
 ·
DOI 
10.1101/2025.11.01.685872
94
%
Reproducible
QED Impressions
This paper passed independent validation.
QED's automated review checked the evidence supporting each claim, the statistical methods, and whether the results are reproducible from the data provided.

It ranks in the top 1% of preprints assessed in Cancer Biology this quarter.
Run full QED analysis
Read paper
Save

Why this is interesting

By enabling single-cell EV proteome tracking via tellurium metabolic labeling, this work reveals that malignant B-cell EVs systematically reprogram myeloid cells through a STAT5-dependent interleukin-receptor triad, redefining how tumors engineer immune tolerance.

Author perspective

What is the most important insight, discovery, or finding from your paper that you would like other scientists to know?
“

A central obstacle in extracellular vesicle (EV) biology has been tracking primary EVs into single recipient cells without perturbing the EVs themselves. In our preprint, we describe TeLEV, an approach that metabolically incorporates a phenylalanine mimic bearing isotopically enriched tellurium into the nascent EV proteome. The label yields a biologically rare, monoisotopic signal detectable with high-dimensional mass cytometry. A single secretome also provides matched, labeled EVs and labeled soluble proteins for single-recipient-cell analysis—a built-in control the field has long lacked. Applied to primary chronic lymphocytic leukemia–derived EVs and to millions of single recipient cells, TeLEV distinguishes EV-driven recipient changes from co-isolated soluble-protein effects, with an initial application pointing to STAT5-dependent immune remodeling. As preprint findings, both the platform and the EV biology have yet to undergo independent peer review.

”
Daniel Bachurski

QED claims analysis

Summary

Tellurium-based metabolic labeling of extracellular vesicle proteomes (TeLEV) enables single-cell tracking of EV uptake across multiple platforms and reveals that malignant B-cell-derived EVs preferentially target myeloid cells to induce a coordinated interleukin receptor triad (CD123, CD127, CD25) and monocyte-derived dendritic cell polarization through STAT5-dependent signaling, with STAT3 acting as a negative regulator of this immunomodulatory program that also upregulates PD-L1 and BCL-2 expression.

See full analysis
Main Claim 1 –

TeLEV Tracks EV Proteomes Across Platforms, Separating Soluble Proteins

Supporting evidence

  • TeLEV Labeling Preserves EV Morphology, Abundance, and Proteome Composition
Main Claim 2 –

Malignant B-Cell EVs Are Preferentially Taken Up by Myeloid Cells

Main Claim 3 –

MBC-EVs Induce CD123/CD127/CD25 Interleukin Receptor Triad in Myeloid Cells

Supporting evidence

  • Biphasic IL-RT Kinetics: Early CD123/CD127, Delayed Sustained CD25
  • MBC-EV IL-RT Enhances IL-2 Responsiveness and STAT5 Phosphorylation
Main Claim 4 –

STAT5 Drives MBC-EV IL-RT Programs, STAT3 Negatively Regulates

Abstract

Extracellular vesicles (EVs) mediate tumor-immune cell communication by carrying protein cargo that can immediately modulate signaling and antigen presentation. Yet mapping the uptake of primary EV proteomes by human immune cells at single-cell resolution has been constrained by a lack of labeling strategies. We show here that TeLEV, a tellurium-based metabolic mass tagging approach that incorporates L-2-tellurienylalanine (TePhe) into EV proteomes, can produce a biologically rare monoisotopic signal, which is detectable by mass cytometry, imaging mass cytometry, and nanoscale SIMS, without perturbing EV morphology, yield, or proteome composition. We applied TeLEV to label primary malignant B-cell-derived EVs (MBC-EVs) from chronic lymphocytic leukemia (CLL) patients and could follow EV uptake by distinct cell populations of healthy donor peripheral blood mononuclear cells. MBC-EV uptake occurred predominantly in cells of myeloid lineages. In direct control experiments with matched secreted proteins, a machine learning approach identified CD123, CD127, and CD25 as key markers distinguishing primary MBC-EV recipients from matched secreted protein recipient cells. Nanoscale imaging enabled localization of EV-delivered proteins within heterochromatin, whereas Te-labeled secreted proteins accumulated in the cytoplasm of recipient cells. We then generated a pan-immune EV uptake atlas by tracing the uptake of primary and cell-line EVs from nine cell lines and six donors with chronic lymphocytic leukemia into 2,977,094 recipient cells across 43 cell types and subpopulations. We found that the uptake of MBC-EVs by myeloid recipients induced monocyte-derived dendritic-cell polarization characterized by the co-expression of the interleukin-receptor triad (IL-RT: CD123, CD127, CD25) identified above. Time-resolved EV uptake analysis showed a rapid, transient expression of CD123/CD127 followed by CD25, both tightly coupled to MBC-EV uptake by myeloid cells. The intensity of IL-RT expression correlated with that of PD-L1 and BCL-2. Using different STAT degraders to bidirectionally modify the EV-induced STAT5 signal, we observed that MBC-EV uptake and IL-RT, PD-L1, and BCL-2 expression increased with STAT3 degradation and decreased with STAT5 degradation. To investigate the functional consequences of the MBC-EV-induced changes, we showed that MBC-EVs in the presence of IL-2 induced a high-CD25 immune state with low cytotoxic and high B cell proliferation. Taken together, TeLEV represents a novel tool for single-cell tracking of EV proteomes, revealing STAT5-dependent immune remodeling of recipient cells.

Related papers

How the QED Score works

QED Score is a validated AI-based quality metric that evaluates life science papers on two dimensions: originality and validity. Each manuscript is anonymized, broken down into its claims and supporting evidence, and examined by specialized AI agents for statistical rigor, consistency across figures, and fit with the existing literature. Scores are percentile ranks, so they're comparable across fields. In blinded tests, expert professors sided with QED Score over journal rank in 75% of decisive cases.
Read the methodology

Free access for academic researchers

Create your free QED account to validate your research, strengthen grant proposals, and uncover scientific insights.
We've sent you an access link.
Please check your inbox.

Didn't get your email? Check your spam folder or reach out to info@qedscience.com

Oops! Something went wrong while submitting the form.
Looking for QED for pharma, biotech or life science organizations?